Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
---|
Brain Neoplasms | 23 | 2024 | 782 | 2.440 |
Why?
|
Glioblastoma | 15 | 2024 | 265 | 2.420 |
Why?
|
Research Design | 9 | 2024 | 599 | 1.890 |
Why?
|
Breast Neoplasms | 9 | 2022 | 3011 | 1.370 |
Why?
|
Biomarkers, Tumor | 12 | 2022 | 1549 | 1.310 |
Why?
|
Lymphoma, Large B-Cell, Diffuse | 3 | 2020 | 154 | 1.210 |
Why?
|
Glioma | 6 | 2023 | 294 | 1.100 |
Why?
|
Triple Negative Breast Neoplasms | 4 | 2022 | 152 | 1.080 |
Why?
|
Biomarkers | 5 | 2023 | 1767 | 0.920 |
Why?
|
Data Interpretation, Statistical | 4 | 2021 | 299 | 0.920 |
Why?
|
Dacarbazine | 10 | 2019 | 102 | 0.890 |
Why?
|
Models, Statistical | 4 | 2017 | 576 | 0.720 |
Why?
|
Statistics as Topic | 1 | 2021 | 234 | 0.700 |
Why?
|
Antineoplastic Agents | 8 | 2021 | 2415 | 0.690 |
Why?
|
Clinical Trials as Topic | 5 | 2024 | 1150 | 0.680 |
Why?
|
Sample Size | 4 | 2017 | 128 | 0.670 |
Why?
|
Antineoplastic Combined Chemotherapy Protocols | 11 | 2022 | 2566 | 0.660 |
Why?
|
Ki-67 Antigen | 3 | 2021 | 66 | 0.650 |
Why?
|
Positron-Emission Tomography | 1 | 2020 | 337 | 0.610 |
Why?
|
Prognosis | 14 | 2021 | 3783 | 0.610 |
Why?
|
Tissue Array Analysis | 2 | 2015 | 127 | 0.600 |
Why?
|
Receptor, ErbB-2 | 5 | 2022 | 246 | 0.580 |
Why?
|
Precision Medicine | 4 | 2023 | 410 | 0.530 |
Why?
|
Humans | 61 | 2024 | 89357 | 0.500 |
Why?
|
Epidemiologic Research Design | 1 | 2014 | 22 | 0.480 |
Why?
|
Biological Specimen Banks | 1 | 2014 | 65 | 0.460 |
Why?
|
Neoplasms | 5 | 2023 | 3041 | 0.450 |
Why?
|
Disease-Free Survival | 11 | 2021 | 1214 | 0.450 |
Why?
|
Biomedical Research | 2 | 2017 | 398 | 0.450 |
Why?
|
Proportional Hazards Models | 7 | 2020 | 851 | 0.440 |
Why?
|
Immunohistochemistry | 3 | 2021 | 1799 | 0.420 |
Why?
|
Molecular Targeted Therapy | 2 | 2013 | 286 | 0.400 |
Why?
|
Clinical Trials, Phase I as Topic | 2 | 2014 | 156 | 0.380 |
Why?
|
Female | 35 | 2022 | 46202 | 0.380 |
Why?
|
Kaplan-Meier Estimate | 7 | 2020 | 860 | 0.380 |
Why?
|
Neoplasm Recurrence, Local | 8 | 2023 | 1365 | 0.380 |
Why?
|
Clinical Trials, Phase II as Topic | 2 | 2012 | 172 | 0.370 |
Why?
|
Maximum Tolerated Dose | 1 | 2011 | 272 | 0.360 |
Why?
|
Computational Biology | 1 | 2013 | 543 | 0.350 |
Why?
|
Neurosurgical Procedures | 6 | 2011 | 232 | 0.350 |
Why?
|
Paraproteinemias | 2 | 2020 | 15 | 0.340 |
Why?
|
Dose-Response Relationship, Drug | 3 | 2019 | 1942 | 0.320 |
Why?
|
Lymphoma, Follicular | 2 | 2019 | 73 | 0.310 |
Why?
|
Aged | 24 | 2020 | 19165 | 0.300 |
Why?
|
Endpoint Determination | 1 | 2007 | 61 | 0.290 |
Why?
|
Predictive Value of Tests | 5 | 2017 | 1723 | 0.280 |
Why?
|
Oligodendroglioma | 2 | 2022 | 45 | 0.280 |
Why?
|
Randomized Controlled Trials as Topic | 3 | 2024 | 838 | 0.280 |
Why?
|
Aged, 80 and over | 13 | 2020 | 6811 | 0.270 |
Why?
|
Middle Aged | 25 | 2021 | 25974 | 0.270 |
Why?
|
Tumor Microenvironment | 2 | 2021 | 463 | 0.270 |
Why?
|
Vincristine | 3 | 2022 | 112 | 0.270 |
Why?
|
Adult | 25 | 2020 | 26607 | 0.260 |
Why?
|
Young Adult | 15 | 2020 | 6312 | 0.250 |
Why?
|
Cyclophosphamide | 3 | 2020 | 302 | 0.250 |
Why?
|
Antibodies, Monoclonal, Humanized | 3 | 2020 | 969 | 0.240 |
Why?
|
Radiotherapy, Adjuvant | 4 | 2013 | 296 | 0.240 |
Why?
|
Prospective Studies | 5 | 2023 | 4289 | 0.230 |
Why?
|
Treatment Outcome | 17 | 2021 | 8241 | 0.220 |
Why?
|
Follow-Up Studies | 9 | 2020 | 3666 | 0.220 |
Why?
|
Meningioma | 1 | 2023 | 63 | 0.220 |
Why?
|
Meningeal Neoplasms | 1 | 2023 | 67 | 0.220 |
Why?
|
Etoposide | 2 | 2020 | 206 | 0.210 |
Why?
|
Prednisone | 2 | 2020 | 259 | 0.210 |
Why?
|
Receptors, Estrogen | 2 | 2021 | 393 | 0.210 |
Why?
|
Male | 25 | 2020 | 42411 | 0.200 |
Why?
|
Chemotherapy, Adjuvant | 5 | 2019 | 487 | 0.200 |
Why?
|
Controlled Clinical Trials as Topic | 1 | 2021 | 22 | 0.200 |
Why?
|
Combined Modality Therapy | 10 | 2020 | 1719 | 0.200 |
Why?
|
British Columbia | 1 | 2021 | 8 | 0.190 |
Why?
|
Medical Oncology | 2 | 2023 | 383 | 0.190 |
Why?
|
Neurology | 1 | 2021 | 74 | 0.180 |
Why?
|
Fluorine Radioisotopes | 1 | 2020 | 25 | 0.180 |
Why?
|
Cyclin D1 | 1 | 2020 | 84 | 0.170 |
Why?
|
Rituximab | 1 | 2020 | 119 | 0.170 |
Why?
|
Bendamustine Hydrochloride | 1 | 2019 | 11 | 0.170 |
Why?
|
Internal Medicine | 1 | 2023 | 355 | 0.170 |
Why?
|
Fluorodeoxyglucose F18 | 1 | 2020 | 142 | 0.170 |
Why?
|
Disease Progression | 6 | 2018 | 1489 | 0.170 |
Why?
|
Monosomy | 1 | 2019 | 12 | 0.170 |
Why?
|
Bortezomib | 1 | 2019 | 82 | 0.160 |
Why?
|
Haploidy | 1 | 2019 | 32 | 0.160 |
Why?
|
Radiopharmaceuticals | 1 | 2020 | 193 | 0.160 |
Why?
|
Capecitabine | 1 | 2019 | 98 | 0.160 |
Why?
|
Astrocytoma | 2 | 2010 | 82 | 0.160 |
Why?
|
Quality of Life | 3 | 2014 | 1668 | 0.160 |
Why?
|
Reproducibility of Results | 5 | 2023 | 2758 | 0.160 |
Why?
|
Chromosomes, Human, Pair 17 | 1 | 2019 | 111 | 0.160 |
Why?
|
Computer Simulation | 2 | 2014 | 1097 | 0.160 |
Why?
|
Magnetic Resonance Imaging | 7 | 2011 | 3448 | 0.150 |
Why?
|
Hodgkin Disease | 1 | 2019 | 181 | 0.150 |
Why?
|
Genomics | 2 | 2013 | 762 | 0.150 |
Why?
|
Antimetabolites, Antineoplastic | 1 | 2019 | 244 | 0.150 |
Why?
|
Survival Analysis | 3 | 2020 | 1534 | 0.140 |
Why?
|
Radiosurgery | 1 | 2020 | 288 | 0.140 |
Why?
|
Lymphocytes, Tumor-Infiltrating | 1 | 2017 | 131 | 0.140 |
Why?
|
DNA Repair Enzymes | 2 | 2013 | 55 | 0.130 |
Why?
|
Tumor Suppressor Protein p53 | 1 | 2019 | 414 | 0.130 |
Why?
|
Neoplasm Staging | 6 | 2021 | 2018 | 0.130 |
Why?
|
Retrospective Studies | 9 | 2019 | 9057 | 0.130 |
Why?
|
CD4-Positive T-Lymphocytes | 1 | 2019 | 445 | 0.130 |
Why?
|
Mutation | 2 | 2019 | 4143 | 0.120 |
Why?
|
Karnofsky Performance Status | 2 | 2011 | 40 | 0.120 |
Why?
|
Multiple Myeloma | 1 | 2019 | 330 | 0.120 |
Why?
|
Indoles | 3 | 2011 | 314 | 0.120 |
Why?
|
Antineoplastic Agents, Alkylating | 3 | 2011 | 138 | 0.120 |
Why?
|
Survival Rate | 6 | 2019 | 1901 | 0.120 |
Why?
|
Risk Assessment | 1 | 2022 | 2303 | 0.120 |
Why?
|
Doxorubicin | 3 | 2019 | 301 | 0.120 |
Why?
|
Monte Carlo Method | 1 | 2014 | 186 | 0.120 |
Why?
|
DNA Modification Methylases | 1 | 2013 | 28 | 0.110 |
Why?
|
T-Lymphocytes | 1 | 2020 | 1224 | 0.110 |
Why?
|
Laboratories | 1 | 2013 | 44 | 0.110 |
Why?
|
Indazoles | 1 | 2013 | 67 | 0.110 |
Why?
|
Drug Discovery | 1 | 2014 | 107 | 0.110 |
Why?
|
Logistic Models | 2 | 2014 | 1213 | 0.110 |
Why?
|
Methylation | 1 | 2013 | 268 | 0.100 |
Why?
|
TOR Serine-Threonine Kinases | 2 | 2011 | 187 | 0.100 |
Why?
|
Interleukin-6 | 1 | 2013 | 261 | 0.100 |
Why?
|
Sulfotransferases | 1 | 2012 | 19 | 0.100 |
Why?
|
Receptor, Platelet-Derived Growth Factor alpha | 1 | 2012 | 12 | 0.100 |
Why?
|
Quinazolines | 1 | 2013 | 221 | 0.100 |
Why?
|
Phosphatidylinositol 3-Kinases | 2 | 2011 | 267 | 0.100 |
Why?
|
Age Factors | 2 | 2019 | 1870 | 0.100 |
Why?
|
Gliosarcoma | 1 | 2011 | 7 | 0.100 |
Why?
|
Genetic Variation | 1 | 2018 | 1374 | 0.100 |
Why?
|
Ependymoma | 1 | 2011 | 18 | 0.100 |
Why?
|
Tumor Suppressor Proteins | 1 | 2013 | 290 | 0.100 |
Why?
|
Sulfonamides | 1 | 2013 | 318 | 0.090 |
Why?
|
Hydroxamic Acids | 1 | 2011 | 51 | 0.090 |
Why?
|
Pyrimidines | 1 | 2013 | 374 | 0.090 |
Why?
|
Radiation-Sensitizing Agents | 1 | 2011 | 97 | 0.090 |
Why?
|
Inositol | 1 | 2010 | 16 | 0.090 |
Why?
|
Supratentorial Neoplasms | 1 | 2010 | 10 | 0.090 |
Why?
|
Histone Deacetylase Inhibitors | 1 | 2011 | 92 | 0.090 |
Why?
|
Exotoxins | 1 | 2010 | 20 | 0.090 |
Why?
|
Gyrus Cinguli | 1 | 2010 | 46 | 0.090 |
Why?
|
Lung Neoplasms | 2 | 2013 | 2362 | 0.090 |
Why?
|
ErbB Receptors | 1 | 2013 | 501 | 0.090 |
Why?
|
Spinal Neoplasms | 1 | 2010 | 49 | 0.090 |
Why?
|
Interleukin-13 | 1 | 2010 | 38 | 0.090 |
Why?
|
Craniotomy | 1 | 2010 | 88 | 0.090 |
Why?
|
Genes, p16 | 1 | 2010 | 11 | 0.090 |
Why?
|
Health Services Needs and Demand | 1 | 2011 | 103 | 0.090 |
Why?
|
Catheters | 1 | 2010 | 76 | 0.090 |
Why?
|
Diffusion Tensor Imaging | 1 | 2010 | 71 | 0.090 |
Why?
|
Central Nervous System Neoplasms | 1 | 2010 | 85 | 0.080 |
Why?
|
Paclitaxel | 2 | 2022 | 479 | 0.080 |
Why?
|
Magnetic Resonance Spectroscopy | 1 | 2010 | 312 | 0.080 |
Why?
|
Caregivers | 1 | 2011 | 160 | 0.080 |
Why?
|
Carcinoma, Renal Cell | 1 | 2013 | 437 | 0.080 |
Why?
|
Chemoradiotherapy | 1 | 2011 | 309 | 0.080 |
Why?
|
Immunologic Factors | 1 | 2010 | 171 | 0.080 |
Why?
|
Proto-Oncogene Proteins B-raf | 1 | 2010 | 146 | 0.080 |
Why?
|
Immunotherapy | 1 | 2014 | 682 | 0.080 |
Why?
|
PTEN Phosphohydrolase | 1 | 2009 | 136 | 0.080 |
Why?
|
Gene Deletion | 1 | 2010 | 342 | 0.080 |
Why?
|
Wound Healing | 1 | 2010 | 359 | 0.080 |
Why?
|
Mutation, Missense | 1 | 2010 | 277 | 0.080 |
Why?
|
Neoadjuvant Therapy | 2 | 2022 | 377 | 0.080 |
Why?
|
In Situ Hybridization, Fluorescence | 2 | 2019 | 354 | 0.080 |
Why?
|
Image Processing, Computer-Assisted | 2 | 2011 | 1242 | 0.070 |
Why?
|
Kidney Neoplasms | 1 | 2013 | 638 | 0.070 |
Why?
|
Pharmacogenetics | 1 | 2011 | 443 | 0.070 |
Why?
|
Inflammation | 1 | 2013 | 972 | 0.070 |
Why?
|
Clinical Trials, Phase III as Topic | 2 | 2022 | 175 | 0.070 |
Why?
|
Intracellular Signaling Peptides and Proteins | 1 | 2009 | 387 | 0.070 |
Why?
|
Neuroblastoma | 1 | 2011 | 395 | 0.070 |
Why?
|
DNA Methylation | 1 | 2011 | 657 | 0.070 |
Why?
|
Bevacizumab | 2 | 2022 | 289 | 0.070 |
Why?
|
Cerebral Cortex | 1 | 2010 | 589 | 0.060 |
Why?
|
Adolescent | 6 | 2019 | 9263 | 0.060 |
Why?
|
Carcinoma, Non-Small-Cell Lung | 1 | 2013 | 1120 | 0.060 |
Why?
|
Neoplasm Grading | 2 | 2019 | 374 | 0.060 |
Why?
|
Antibodies, Monoclonal | 1 | 2010 | 1412 | 0.060 |
Why?
|
Cell Line, Tumor | 3 | 2019 | 2558 | 0.060 |
Why?
|
Gene Expression Regulation | 1 | 2012 | 1976 | 0.050 |
Why?
|
Odds Ratio | 2 | 2018 | 683 | 0.050 |
Why?
|
Lomustine | 1 | 2022 | 26 | 0.050 |
Why?
|
Procarbazine | 1 | 2022 | 40 | 0.050 |
Why?
|
Signal Transduction | 2 | 2012 | 3385 | 0.050 |
Why?
|
International Cooperation | 2 | 2013 | 125 | 0.050 |
Why?
|
Cell Proliferation | 3 | 2012 | 1652 | 0.050 |
Why?
|
Immunoenzyme Techniques | 2 | 2011 | 306 | 0.050 |
Why?
|
Risk Factors | 1 | 2011 | 5499 | 0.050 |
Why?
|
Carboplatin | 1 | 2022 | 312 | 0.050 |
Why?
|
Analysis of Variance | 2 | 2014 | 899 | 0.050 |
Why?
|
Neoplasm, Residual | 1 | 2022 | 181 | 0.050 |
Why?
|
Information Dissemination | 1 | 2021 | 114 | 0.050 |
Why?
|
Trastuzumab | 1 | 2020 | 74 | 0.040 |
Why?
|
Postoperative Complications | 1 | 2010 | 2284 | 0.040 |
Why?
|
DNA, Neoplasm | 2 | 2011 | 268 | 0.040 |
Why?
|
Statistics, Nonparametric | 2 | 2011 | 306 | 0.040 |
Why?
|
Vinblastine | 1 | 2019 | 108 | 0.040 |
Why?
|
Bleomycin | 1 | 2019 | 102 | 0.040 |
Why?
|
Tumor Necrosis Factor Receptor Superfamily, Member 7 | 1 | 2019 | 3 | 0.040 |
Why?
|
Blotting, Western | 2 | 2011 | 794 | 0.040 |
Why?
|
Cohort Studies | 3 | 2010 | 2872 | 0.040 |
Why?
|
Societies, Medical | 1 | 2023 | 575 | 0.040 |
Why?
|
B7-H1 Antigen | 1 | 2021 | 274 | 0.040 |
Why?
|
Mice, Nude | 2 | 2011 | 815 | 0.040 |
Why?
|
Karyotype | 1 | 2019 | 34 | 0.040 |
Why?
|
Chromosome Banding | 1 | 2018 | 74 | 0.040 |
Why?
|
CD28 Antigens | 1 | 2019 | 90 | 0.040 |
Why?
|
Methotrexate | 1 | 2019 | 250 | 0.040 |
Why?
|
Radiotherapy | 2 | 2011 | 333 | 0.040 |
Why?
|
Genes, myc | 1 | 2018 | 39 | 0.040 |
Why?
|
Gene Expression Profiling | 1 | 2023 | 1431 | 0.040 |
Why?
|
Gene Rearrangement | 1 | 2018 | 173 | 0.040 |
Why?
|
Fluorouracil | 1 | 2019 | 561 | 0.040 |
Why?
|
Drug Administration Schedule | 1 | 2019 | 895 | 0.040 |
Why?
|
Programmed Cell Death 1 Receptor | 1 | 2019 | 171 | 0.040 |
Why?
|
Time Factors | 2 | 2020 | 5338 | 0.040 |
Why?
|
Remission Induction | 1 | 2019 | 740 | 0.040 |
Why?
|
Chromosome Aberrations | 1 | 2018 | 390 | 0.040 |
Why?
|
Receptors, Progesterone | 1 | 2017 | 174 | 0.030 |
Why?
|
Alleles | 1 | 2020 | 1135 | 0.030 |
Why?
|
Estrogen Receptor alpha | 1 | 2017 | 148 | 0.030 |
Why?
|
Neoplasm Metastasis | 1 | 2020 | 1109 | 0.030 |
Why?
|
Transcriptome | 1 | 2020 | 630 | 0.030 |
Why?
|
Neoplasm Invasiveness | 1 | 2017 | 576 | 0.030 |
Why?
|
Confidence Intervals | 1 | 2014 | 225 | 0.030 |
Why?
|
Cells, Cultured | 1 | 2019 | 2884 | 0.030 |
Why?
|
National Cancer Institute (U.S.) | 1 | 2013 | 73 | 0.030 |
Why?
|
Survival | 1 | 2013 | 21 | 0.030 |
Why?
|
Evaluation Studies as Topic | 1 | 2013 | 270 | 0.030 |
Why?
|
Child, Preschool | 2 | 2011 | 3731 | 0.030 |
Why?
|
Checklist | 1 | 2013 | 61 | 0.030 |
Why?
|
High-Throughput Screening Assays | 1 | 2013 | 58 | 0.030 |
Why?
|
Mice | 3 | 2012 | 11761 | 0.030 |
Why?
|
Specimen Handling | 1 | 2013 | 102 | 0.030 |
Why?
|
Bayes Theorem | 1 | 2014 | 370 | 0.030 |
Why?
|
Guidelines as Topic | 1 | 2013 | 160 | 0.030 |
Why?
|
Animals | 4 | 2014 | 27371 | 0.030 |
Why?
|
Sulfatases | 1 | 2012 | 3 | 0.030 |
Why?
|
Heparan Sulfate Proteoglycans | 1 | 2012 | 21 | 0.030 |
Why?
|
Observer Variation | 1 | 2013 | 610 | 0.020 |
Why?
|
Polymorphism, Single Nucleotide | 1 | 2020 | 2401 | 0.020 |
Why?
|
Chemoradiotherapy, Adjuvant | 1 | 2011 | 35 | 0.020 |
Why?
|
Tumor Stem Cell Assay | 1 | 2011 | 37 | 0.020 |
Why?
|
Gamma Rays | 1 | 2011 | 73 | 0.020 |
Why?
|
Acetylation | 1 | 2011 | 132 | 0.020 |
Why?
|
Genetic Predisposition to Disease | 1 | 2020 | 2340 | 0.020 |
Why?
|
Histone Deacetylases | 1 | 2011 | 70 | 0.020 |
Why?
|
Sensation Disorders | 1 | 2010 | 24 | 0.020 |
Why?
|
Luminescent Proteins | 1 | 2011 | 144 | 0.020 |
Why?
|
Choline | 1 | 2010 | 24 | 0.020 |
Why?
|
Intraoperative Period | 1 | 2010 | 90 | 0.020 |
Why?
|
Movement Disorders | 1 | 2010 | 44 | 0.020 |
Why?
|
Software | 1 | 2014 | 665 | 0.020 |
Why?
|
Drug Synergism | 1 | 2011 | 306 | 0.020 |
Why?
|
Neuronavigation | 1 | 2010 | 22 | 0.020 |
Why?
|
Risk Management | 1 | 2010 | 43 | 0.020 |
Why?
|
Muscle Weakness | 1 | 2010 | 60 | 0.020 |
Why?
|
Forkhead Transcription Factors | 1 | 2011 | 171 | 0.020 |
Why?
|
Adaptation, Psychological | 1 | 2011 | 166 | 0.020 |
Why?
|
Tomography, X-Ray Computed | 1 | 2020 | 2661 | 0.020 |
Why?
|
Functional Laterality | 1 | 2010 | 200 | 0.020 |
Why?
|
Activities of Daily Living | 1 | 2011 | 207 | 0.020 |
Why?
|
Tumor Burden | 1 | 2011 | 308 | 0.020 |
Why?
|
Perfusion | 1 | 2010 | 236 | 0.020 |
Why?
|
Sulfites | 1 | 2009 | 31 | 0.020 |
Why?
|
Cell Survival | 1 | 2012 | 983 | 0.020 |
Why?
|
Nervous System Diseases | 1 | 2010 | 162 | 0.020 |
Why?
|
Xenograft Model Antitumor Assays | 1 | 2011 | 470 | 0.020 |
Why?
|
Tumor Cells, Cultured | 1 | 2011 | 1057 | 0.020 |
Why?
|
Microsurgery | 1 | 2010 | 88 | 0.020 |
Why?
|
Polymerase Chain Reaction | 1 | 2011 | 922 | 0.020 |
Why?
|
Flow Cytometry | 1 | 2011 | 691 | 0.020 |
Why?
|
Gene Silencing | 1 | 2010 | 178 | 0.020 |
Why?
|
Cytokines | 1 | 2013 | 803 | 0.020 |
Why?
|
Serine | 1 | 2009 | 104 | 0.020 |
Why?
|
Gene Dosage | 1 | 2010 | 208 | 0.020 |
Why?
|
Child | 2 | 2011 | 7174 | 0.020 |
Why?
|
Linear Models | 1 | 2010 | 421 | 0.020 |
Why?
|
Histones | 1 | 2011 | 329 | 0.020 |
Why?
|
Drug Therapy, Combination | 1 | 2011 | 784 | 0.020 |
Why?
|
Sickness Impact Profile | 1 | 2008 | 26 | 0.020 |
Why?
|
Recombinant Fusion Proteins | 1 | 2010 | 565 | 0.020 |
Why?
|
Mice, Transgenic | 1 | 2012 | 1574 | 0.020 |
Why?
|
Enzyme Inhibitors | 1 | 2011 | 645 | 0.020 |
Why?
|
Patient Satisfaction | 1 | 2011 | 461 | 0.020 |
Why?
|
Emotions | 1 | 2011 | 349 | 0.020 |
Why?
|
Brain Mapping | 1 | 2010 | 564 | 0.020 |
Why?
|
Case-Control Studies | 1 | 2011 | 1862 | 0.020 |
Why?
|
Phosphorylation | 1 | 2009 | 1132 | 0.020 |
Why?
|
Models, Biological | 1 | 2013 | 1765 | 0.020 |
Why?
|
Sensitivity and Specificity | 1 | 2010 | 2015 | 0.020 |
Why?
|
Image Interpretation, Computer-Assisted | 1 | 2010 | 688 | 0.020 |
Why?
|
Longitudinal Studies | 1 | 2008 | 1072 | 0.020 |
Why?
|
Infant | 1 | 2011 | 3160 | 0.010 |
Why?
|
Apoptosis | 1 | 2011 | 1717 | 0.010 |
Why?
|
Gene Expression Regulation, Neoplastic | 1 | 2009 | 1265 | 0.010 |
Why?
|
Surveys and Questionnaires | 1 | 2011 | 2624 | 0.010 |
Why?
|
Brain | 1 | 2011 | 2285 | 0.010 |
Why?
|
United States | 1 | 2013 | 6989 | 0.010 |
Why?
|